A brain-stimulation device sold as a regulated medical device in Europe and a wellness product in the United States shows how the label, not the hardware, decides what a buyer is entitled to know.

A proposed amendment to Britain's cyber bill puts the duty on organizations that deploy AI agents, while the incidents that prompted it were found, and reported, by the companies that build them.

Life Biosciences has treated its first patients with a gene therapy that tries to rewind cells. Three people and fifty-six days say less than the headlines suggest, and the design says more.

The FDA's draft path for individualized gene editing is a pre-approved change process for the human genome, and every pre-approved process has a boundary somebody owns.

A new Nature Neuroscience study decodes speech and body language from the same patch of cortex. The hard part is no longer reading the signal. It is deciding what the signal is allowed to move.